WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca today announced the results of DERIVE, a Phase 3 study that evaluated the efficacy and safety of FARXIGA ® (dapagliflozin 10 mg), in patients with ...

and AstraZeneca (NYSE: AZN) today announced results from two 24-week Phase 3 clinical studies examining the investigational compound dapagliflozin at 5 mg or 10 mg (clinical trial dose ...

Bristol-Myers Squibb and AstraZeneca announced positive results ... mg/dL for dapagliflozin 5 mg and -23.5 mg/dL /dl for dapagliflozin 10 mg, compared to -6.0 mg/dL for placebo.

Dapagliflozin, an investigational compound, is a potential first-in-class sodium-glucose cotransporter-2 (SGLT2) inhibitor currently in Phase 3 trials under joint development by Bristol-Myers ...

and AstraZeneca (NYSE: AZN) today announced results from a Phase 3 clinical study that showed the investigational compound dapagliflozin 10 mg demonstrated significant reductions in blood sugar ...

5 mg or 10 mg once-daily dapagliflozin — a selective inhibitor of sodium-glucose cotransporter 2 that is being developed by AstraZeneca and Bristol-Myers Squibb. Of the 800 participants analyzed ...

After that, Heerspink's group only continued with part B of the trial: zibotentan 1.5 mg plus dapagliflozin 10 mg/day and zibotentan ... The trial was funded by AstraZeneca. Some co-authors ...

The SGLT2 inhibitors, as a class, lead to similar treatment benefits at comparable clinical doses, although there are some discrepancies between them, particularly when dapagliflozin (Farxiga; ...

Patients were randomly assigned to calorie restriction with dapagliflozin 10 mg/day or placebo ... The study was partially funded by AstraZeneca, the manufacturer of dapagliflozin.

Among patients who have heart failure with preserved ejection fraction (HFpEF), 24 weeks of treatment with dapagliflozin (Farxiga; AstraZeneca ... treatment with either placebo or dapagliflozin 10 mg ...

dapagliflozin (10 mg) alone, taken daily over 12 weeks. Key endpoints include change from baseline in UACR at week 12 and fluid retention throughout the trial. AstraZeneca in CVRM Cardiovascular, ...